Coronary Stent Market Size, | Industry Analysis Report 2032
Global Coronary Stent Market Size, Share Analysis Report, 2024-2032

Coronary Stent Market Share, Size, Trends, Industry Analysis Report, By Product (Drug Eluting Stents, Bioresorbable Vascular Scaffold Stents, Bare Metal Stents); By Metal; By Biomaterial; By End-Use; By Region; Segment Forecast, 2024 - 2032

  • Published Date:Jan-2024
  • Pages: 114
  • Format: PDF
  • Report ID: PM1701
  • Base Year: 2023
  • Historical Data: 2019-2021

Report Outlook

The global coronary stent market was valued at USD 8306.55 million in 2023 and is expected to grow at a CAGR of 4.40% during the forecast period.

A coronary stent is a specialized medical device used to treat coronary artery disease (CAD), characterized by the narrowing or blockage of the coronary arteries that supply blood to the heart muscle. This narrowing or blockage is typically caused by plaque accumulation of cholesterol, fat, calcium, and other substances.

Coronary Stent Market Size

To Understand More About this Research: Request a Free Sample Report

Several factors are driving the growth of the coronary stent market. First, cardiovascular diseases, including CAD, are increasing, which creates a greater demand for effective treatment options such as coronary stents. Additionally, favorable government initiatives to improve cardiac care and the rising number of cardiac surgeries contribute to market growth. The aging population, more susceptible to heart-related ailments, further fuels the demand for coronary stents.

Furthermore, individuals with diabetes often require ongoing medical attention due to increased hospitalization rates. It, in turn, contributes to the higher demand for coronary stents, as they are frequently used in treating diabetic patients with coronary artery disease.

In terms of stent properties, an ideal stent should possess various characteristics. These include a good expandability ratio, flexibility, radiopacity (visible under medical imaging), non-toxicity, excellent drug delivery capabilities, radial loop strength, and high sensitivity to blood clotting (thrombo-sensitivity) with minimal recoil after deployment. These features ensure the stent's effectiveness and safety in treating coronary artery disease.

During the initial pandemic outbreak and periods of high local COVID-19 case count, various states, towns, and nations implemented shelter-in-place orders and restrictions to minimize the potential exposure and transmission of the virus. It postponed elective surgeries, including percutaneous coronary intervention (PCI) procedures. Consequently, the total volume of PCI procedures and the sales and revenues of coronary stents experienced a significant decline in 2020. However, as healthcare facilities gradually resume semi-elective and non-urgent methods and increase their capacity utilization, the gains from coronary stents are expected to rebound.

Stenting technology has gained preference over conventional balloon angioplasty due to the introduction of advanced drug-eluting stents (DES) and the development of bioresorbable scaffolds. Technological advancements in creating bifurcated stents using biodegradable materials have led to more efficient and improved outcomes in treating cardiovascular disease (CVD). Companies are actively engaged in product development, partnerships, and strategic collaborations to enhance coronary stent technology further. These factors are expected to drive market growth in the forecast period.

  • For instance, B Braun and the vascular system have engaged in research and development activities with the Clinical Research Institute and the Center of Cardiovascular Diseases in Rotenburg an der Fulda, Germany, for "The Paclitaxel-Eluting Corofle DES Study II," an acute and six-month clinical trial that has been extended for one year.

Furthermore, the growing preference for minimally invasive surgeries (MIS) is anticipated to drive the adoption of coronary stents in the forecast period. Due to higher patient satisfaction, MIS procedures offer advantages, such as smaller incisions. These procedures also result in shorter hospital stays and faster recovery times.

Coronary Stent Market Share, Size

For Specific Research Requirements,  Request for a Customized Report

Industry Dynamics

Growth Drivers

Increasing Prevalence of Coronary Heart Diseases across the Globe will facilitate market growth

The market growth of coronary stents during the forecast period is primarily driven by the increasing prevalence of coronary heart disorders worldwide. Unhealthy eating habits, sedentary lifestyles, and rising stress levels contribute to the growing incidence of heart disorders. In the United States, heart disease is the highest cause of death. According to the Centers for Disease Control and Prevention (CDC), approximately 647,000 people in the U.S. die from heart disease yearly, with more than 18 million suffering from cardiovascular diseases. Coronary heart disorder is the most common form of cardiovascular disease, causing 365,914 deaths in 2017. The rising patient pool and prevalence of heart ailments are expected to drive the lucrative growth of the coronary stent market during the forecast period.

In addition, Contract Research Organizations (CROs) traditionally focused on conducting clinical trials to assess the efficacy and safety of coronary stents. However, these establishments are crucial in assisting manufacturers in developing these devices. They are also collaborating with regulatory agencies to expedite market approvals for coronary stents, thereby reducing the duration of the regulatory approval process.

Report Segmentation

The market is primarily segmented based on product, metal, biomaterial, end-use, and region.

By Product

By Metal

By Biomaterial

By End-Use

By Region

  • Drug Eluting Stents
    • Biodegradable
    • Non-Biodegradable
  • Bioresorbable Vascular Scaffold Stents
  • Bare Metal Stents
  • Covered Stents
  • Others
  • Cobalt Chromium
  • Platinum Chromium
  • Nickel Titanium
  • Stainless Steel
  • Metallic biomaterials
  • Polymers biomaterials
  • Natural biomaterials
  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiology Centers
  • Specialty Clinics
  • Others
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

To Understand the Scope of this Report: Speak to Analyst

By Product Analysis

The Drug-Eluting Stents (DES) segment held the largest revenue share in 2022

In 2022, the Drug-Eluting Stents (DES) segment held the largest revenue share. The continuous advancements and introduction of new devices are pivotal in solidifying DES as the preferred choice for PCI procedures. The competition in the market is actively developing and launching technologically developed DES options. Notable launches include Abbott Laboratories' Medtronic's Resolute Onyx, Boston Scientific's Synergy, and XIENCE Skypoint. These new DES offer improved stent integrity, enhanced deliverability, and lower complication rates than previous-generation devices.

On the other hand, the bioresorbable stent segment is expected to witness substantial growth throughout the forecast period. The increasing prevalence of cardiac disorders on a global scale is a key driver for the demand for bioresorbable stents. Additionally, the growing elderly population is another significant factor fueling market growth, as individuals over 60 are more prone to chronic ailments, including cardiovascular diseases. Therefore, these factors are expected to contribute to the expansion of the market during the analysis period.

By End-Use Analysis

The hospital segment accounted for the highest market share in 2022

The hospital segment accounted for the highest market share in 2022, primarily driven by the increasing number of critical surgeries, including angioplasty, predominantly performed in hospital settings. Hospitals possess advanced facilities for complex procedural interventions, making them the preferred choice. Additionally, the segment's growth is further stimulated by the increasing number of partnerships with major market players. However, the outbreak of the coronavirus in 2022 has resulted in the postponement of several elective cardiac procedures, which may prime to relatively sluggish growth in this segment.

On the other hand, specialty clinics are anticipated to experience significant growth throughout the forecast period. This growth can be attributed to several factors, including the increasing number of specialty clinics and a rising number of cardiologists worldwide. Furthermore, individuals are increasingly aware of coronary stents' various benefits, attracting a larger patient pool to these specialized facilities. As a result, the specialty clinics segment is poised for substantial growth during the forecast period.

Regional Insights

North America dominated the largest market in 2022

In 2022, North America dominated the largest market contributor in the vascular access devices market, with the United States foremost in revenue. Cardiovascular diseases (CVDs) are the foremost cause of death in the North American region. The American Heart Association (AHA) estimates that approximately 85.6 million people in the US are affected by CVD—the associated costs, including healthcare expenditures and productivity losses, amount to around USD 318 billion. To diagnose and treat these complex diseases, physicians commonly perform angiography, which involves the insertion of catheters in the femoral and radial sites and using coronary stents when necessary.

The adoption of coronary stents in the Asia-Pacific (APAC) region is accounted for the fastest growth due to the increasing dominance of local vendors. Countries such as India, Japan, and China are major contributors to the market revenue in APAC. The key drivers of the market in this region are the growing number of cardiovascular procedures, including stenting, driven by an aging population, as well as the availability of stents at lower costs and government regulations capping the prices of coronary stents in India.

Countries like India, China, Thailand, Singapore, and South Korea have become medical tourism hotspots. It has prompted many industry players to focus on expanding their operations in these countries. With their rapid emergence, these countries are expected to dominate the market during the forecast period.

Key Market Players & Competitive Insights

The market is characterized by intense competition, with established players relying on advanced technology, high-quality products, and a strong brand image to drive revenue growth. These companies employ various strategies such as research and development, mergers and acquisitions, and technological innovations to expand their product portfolios and maintain a competitive edge in the market.

Some of the major players operating in the global market include:

  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Biosensors International Group (acquired by Blue Sail Medical Co., Ltd)
  • Biotronik SE & Co.KG
  • Boston Scientific Corporation
  • C. R. Bard, Inc.
  • Cook Medicals
  • Lepu Medicals
  • Liaoning Biomedical Materials
  • Medtronic Plc
  • Meril Life Sciences
  • MicroPort Scientific Corporation
  • Shandong JW Medical Systems
  • Stentys SA
  • Terumo Corporation
  • Translumina GmbH
  • Vascular Concepts

Recent Developments

  • In April 2021, Abbott unveiled the European launch of the Ultreon 1.0 Software, a coronary imaging platform powered by artificial intelligence (AI). This innovative software is designed to enhance the detection of calcium-based blockages and accurately measure vessel diameter during coronary stenting procedures.
  • In February 2021, The Cardiovascular Systems Inc. announced a partnership with Chansu Vascular Technologies, LLC. This collaboration aims to develop drug-coated balloons for peripheral and coronary applications, specifically in conjunction with drug-eluting stents. This strategic partnership aims to leverage the expertise and resources of both companies to advance the field of interventional cardiology and enhance treatment options for patients requiring drug-eluting stents.
  • In May 2022, Medtronic plc obtained approval from the FDA for its Onyx Frontier drug-eluting stent. The Onyx Frontier stent features an advanced delivery system designed to improve its deliverability and enhance acute performance during stent placement procedures. This approval by the FDA highlights the safety and efficacy of the Onyx Frontier stent, further solidifying Medtronic's commitment to providing innovative solutions for cardiovascular interventions.

Coronary Stent Market Report Scope

Report Attributes


Market size value in 2024

USD 8649.61 million

Revenue forecast in 2032

USD 12,248.80 million


4.40% from 2024 – 2032

Base year


Historical data

2019 – 2021

Forecast period

2024 – 2032

Quantitative units

Revenue in USD million and CAGR from 2024 to 2032

Segments Covered

By Product, By Metal, By Biomaterial, By End-Use, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key Companies

The Shave Wall Company, Electric Mirror Inc., Toilet Tree Product, Roper Rhodes Abbott Laboratories, B. Braun Melsungen AG, Biosensors International Group (acquired by Blue Sail Medical Co., Ltd), Biotronik SE & Co.KG, Boston Scientific Corporation, Cook Medicals, C. R. Bard, Inc., Lepu Medicals, Liaoning Biomedical Materials, Medtronic Plc, Meril Life Sciences, MicroPort Scientific Corporation, Shandong JW Medical Systems, Stentys SA, Terumo Corporation, Translumina GmbH, Vascular Concepts


key companies in coronary stent market are Abbott Laboratories, B. Braun Melsungen AG, Biosensors International Group (acquired by Blue Sail Medical Co., Ltd), Biotronik SE & Co.KG, Boston Scientific Corporation, C. R. Bard, Inc.

The global coronary stent market is expected to grow at a CAGR of 4.4% during the forecast period.

The coronary stent market report covering key segments are product, metal, biomaterial, end-use, and region.

key driving factors in coronary stent market are increasing Prevalence of Coronary Heart Diseases across the Globe will Facilitate Market Growth

The global coronary stent market size is expected to reach USD 12,248.80 million by 2032.